A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder - NCT05064878

The median percentage change from the Baseline Period (Baseline) in "monthly (28 days) countable motor seizure frequency, The percentage of subjects who achieve a ≥ 50% reduction from Baseline in CMSF, The percentage of subjects who achieve improvement in the Clinical Global Impression-Improvement (CGI-I) rating as assessed by the Investigator, The median percentage change from Baseline in monthly Generalized Tonic-Clonic (GTC) seizure frequency